Copyright
©2014 Baishideng Publishing Group Co.
World J Gastroenterol. Mar 28, 2014; 20(12): 3100-3111
Published online Mar 28, 2014. doi: 10.3748/wjg.v20.i12.3100
Published online Mar 28, 2014. doi: 10.3748/wjg.v20.i12.3100
Table 4 Studies of liver tumors including hepatocellular carcinoma, cholangiocarcinoma, and liver metastasis
| Ref. | Country | Study design | Tumors(patient number) | Median volume (mL) | Median size (cm) | Median dose (range)/fraction, Gy | Median follow-up (range) (mo) | Local control | Overall survival |
| Blomgren et al[24], 1995 | Sweden | Retrospective | HCC+CCC/metastasis(20/21) | 22 | - | Fixed30 Gy/2-3 fr | 11 | HCC + CCC: 100%Metastasis: 95% | - |
| Tse et al[28], 2008 | Canada | Phase I | HCC/CCC(31/10) | 173(9-1913) | - | VariableMedian 36 (24-54) Gy/6 fr | 18(11-39) | 65% (1 yr) | 48% (1 yr) |
| Herfarth et al[47], 2001 | Germany | Phase I-II | HCC/CCC(4/54) | 10 (1-132) | - | Dose escalation14-26 Gy/1 fr | 6(1-26) | 81%(18 mo) | - |
| Wulf et al[48], 2006 | Switzerland | Prospective | HCC + CCC/metastasis(5/51) | HCC+CCC: 14-516Metastasis: 9-355 | - | VariableLow dose:30 Gy/3 fr or28 Gy/4 frHigh dose: 36-38 Gy/3 fr or26 Gy/1 fr | HCC + CCC:15 (2-48)Metastasis:15 (2-85) | HCC + CCC: 100%Metastasis: 99% (1 yr), 66% (2 yr) | 72% (1 yr)32% (2 yr) |
| Méndez-Romero et al[49], 2006 | The Netherland | Retrospective | HCC/metastasis(11/34) | 22(10-322) | 3.2(0.5-7.2) | VariableNo cirrhosis and ≥ 4 cm: 37.5 Gy/3 frCirrhosis and< 4 cm: 25 Gy/5 fr or30 Gy/3 fr | 13(0.5-31) | 94% (1 yr)82% (2 yr) | HCC: 75%(1 yr), 40% (2 yr)Metastasis: 82% (1 yr), 54% (2 yr) |
| Iwata et al[50], 2010 | Japan(Nagoya City University) | Retrospective | HCC/metastasis(6/12) | - | 2.3(1.2-3.5) | Variable50 or 55 Gy/10 fr | 15 | 86% (1 yr) | 94% (1 yr) |
| Goodman et al[51], 2010 | United States (Memorial Sloan Kettering Cancer Center) | Phase I | HCC/metastasis(2/24) | 33(0.8-147) | Dose escalation18-30 Gy/1 fr | 17(2-55) | 77% (1 yr) | 50% (2 yr) | |
| Dewas et al[53], 2012 | France | Retrospective | HCC + CCC/metastasis(54/99) | 32(0.2-500) | 3.3(0.5-11) | Variable45 Gy/3 fr | 15(12-18) | 84% (1 yr)75% (2 yr) | - |
| Ibarra et al[54], 2012 | United States (Cleveland) | Retrospective, multicenter | HCC/CCC(21/11) | HCC: 334 (10-1914)CCC: 80 (31-819) | - | HCC: 22 (18-26) Gy/1 frCCC: 30 (22-30) Gy/1 fr | 13(0.5-54) | 84% (1 yr)75% (2 yr) | 87% (1 yr)55% (2 yr) |
- Citation: Sanuki N, Takeda A, Kunieda E. Role of stereotactic body radiation therapy for hepatocellular carcinoma. World J Gastroenterol 2014; 20(12): 3100-3111
- URL: https://www.wjgnet.com/1007-9327/full/v20/i12/3100.htm
- DOI: https://dx.doi.org/10.3748/wjg.v20.i12.3100